好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Impact of Social Determinants of Health in the Morbidity of Patients with Huntington Disease
Movement Disorders
P6 - Poster Session 6 (8:00 AM-9:00 AM)
3-001
To characterize clinical outcomes in patients with Huntington disease (HD) using individual and neighborhood-level indicators.

The distribution of HD according to variables such as age, sex, race, and ethnicity has been documented. However, evidence about the association of socioeconomic status and motor, cognitive, behavioral, functional, and independence outcomes according to the social vulnerability index (SVI) is missing.

This is a cross-sectional study. HD pathogenic-variant carriers from the UTHealth Houston Huntington Disease Society of America Center of Excellence participating in Enroll-HD were included in the study. We included clinical data derived from the Unified Huntington Disease Rating Scale (UHDRS). The SVI was calculated based on the participant’s current address. Associations between dichotomous variables were assessed with the Chi-Square or Fisher's exact test.

We included 131 participants with a confirmed diagnosis of HD. Mean age was 45.6 years, with 58.7% identified as females. Patients with less educational years had an SVI > 50th percentile (p = 0.0004). Interestingly, patients with an SVI > 50th percentile had lower correct responses in the Categorical Verbal Fluency test (p = 0.0405). Patients with an SVI > 75th percentile had lower scores in the TFC section of the UHDRS (p = 0.029). There was a significant correlation between lower years of education (ρ = -0.398, p < 0.001) and less correct responses in the verbal fluency task (ρ = -0.189, p = 0.036) and higher SVI. There was a significant difference regarding SVI between White individuals and African-Americans, Hispanic/Latino, American-Indian, and Asian participants (p = 0.047).

Socioeconomic factors play an important role in the morbidity of patients with HD. The SVI is an important way of addressing the needs of the patients based on their location, which can lead to the creation of public policies to treat modifiable risk factors and improve their quality of life. 

Authors/Disclosures
Jorge E. Patino Murillas, MD (University of Cincinnati)
PRESENTER
Dr. Patino Murillas has nothing to disclose.
Natalia Pessoa Rocha Natalia Pessoa Rocha has nothing to disclose.
Shayan A. Zadegan, MD Dr. Zadegan has nothing to disclose.
Brittany Duncan (The University of Texas Health Science Center at Houston) No disclosure on file
Ryan Ramphul (UTHealth Houston School of Public Health) Ryan Ramphul has nothing to disclose.
Anjail Sharrief, MD (University of Texas) The institution of Dr. Sharrief has received research support from NIH. The institution of Dr. Sharrief has received research support from University of Houston . Dr. Sharrief has a non-compensated relationship as a Consultant with Abbott that is relevant to AAN interests or activities.
Erin Furr-Stimming, MD, FAAN (University of Texas Health Science Center-Houston) Dr. Furr-Stimming has received personal compensation for serving as an employee of Help4HD International. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedPage. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Latus Bio. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atalanta Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SkyHawk Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atalanta Therapeutics. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine Bioscienes. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. The institution of Dr. Furr-Stimming has received research support from HDSA. The institution of Dr. Furr-Stimming has received research support from Prilennia. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has a non-compensated relationship as a Committee member with AAN UES Committee that is relevant to AAN interests or activities.